Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
gene silencing
Biotech
Alnylam, Biogen build noise in Alzheimer's with gene silencing
Alnylam and Biogen published early-phase data on their respective RNAi and antisense approaches to treating the neurodegenerative disease.
Nick Paul Taylor
Oct 26, 2023 8:51am
Lilly doubles down on ProQR's RNA tech in $75M deal expansion
Dec 22, 2022 10:38am
Alnylam, Regeneron hit go on genetic NASH therapy phase 2
Sep 15, 2022 8:09am
Chinese powerhouse continues charge into siRNA with Silence pact
Oct 15, 2021 7:15am
Eli Lilly follows up MiNA pact with a 2nd $1B-plus RNA collab
Sep 8, 2021 4:01pm
Biogen, Genentech ally with new neurodegenerative biotech
Jan 11, 2021 9:15am
